

## STEP THERAPY POLICY

- POLICY:** Gout Medications Step Therapy Policy
- Uloric® (febuxostat tablets – Takeda, generic)
  - Zyloprim® (allopurinol tablets – Casper, generic)

**REVIEW DATE:** 01/18/2023

---

### OVERVIEW

Allopurinol (Zyloprim, generic), a xanthine oxidase inhibitor, is indicated for the following uses:<sup>1</sup>

- **Signs and symptoms of primary or secondary gout** (e.g., acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy).
- **Cancer therapy which causes elevations on serum and urinary uric acid levels**, of patients with leukemia, lymphoma, and malignancies.
- **Recurrent calcium oxalate calculi**, whose daily uric acid excretion exceeds 800 mg/day for male patients and 750 mg/day for female patients.

Febuxostat (Uloric, generic), a xanthine oxidase inhibitor, is indicated for the **chronic management of hyperuricemia in patients with gout** who have had an inadequate response to a maximally titrated dose of allopurinol, or for whom treatment with allopurinol is not advisable.<sup>2</sup>

### POLICY STATEMENT

This program has been developed to encourage the use of a Step 1 Product prior to the use of a Step 2 Product. If the Step Therapy rule is not met for a Step 2 Product at the point of service, coverage will be determined by the Step Therapy criteria below. All approvals are provided for 1 year in duration.

**Automation:** A patient with a of one Step 1 Product within the 130-day look-back period is excluded from Step Therapy.

**Step 1:** allopurinol tablets (Zyloprim, generic)

**Step 2:** febuxostat tablets (Uloric, generic)

### CRITERIA

1. If the patient has tried one Step 1 Product, approve a Step 2 Product.
2. If the patient is receiving concomitant medications that have significant drug-drug interactions with the Step 1 Product, which are not noted with Uloric/febuxostat tablets (e.g., cyclosporine, chlorpropamide), approve the Step 2 Product.
3. No other exceptions are recommended.

01/18/2023

© 2022. All Rights Reserved.

This document is confidential and proprietary. Unauthorized use and distribution are prohibited.

**REFERENCES**

1. Zyloprim® tablets [prescribing information]. Greenville, NC: Casper; December 2018.
2. Uloric® tablets [prescribing information]. Deerfield, IL: Takeda; February 2019.